Please login to the form below

Not currently logged in
Email:
Password:

AZ integrates Cambridge Antibody Technology into MedImmune

AstraZeneca integrates Cambridge Antibody Technology into its global biologics business under the MedImmune banner

Anglo-Swedish pharmaceutical company AstraZeneca (AZ) has integrated UK-based biopharmaceutical company Cambridge Antibody Technology (CAT) into its global biologics business under the MedImmune banner.

The new business unit will unite the resources and expertise from CAT, MedImmune and other biologics activities within AZ.

With the revised structure, AZ has created a biotech with total revenues of over USD 1.3bn FY06, a pipeline of approximately 100 research projects and more than 12 clinical product candidates. The new entity also employs 3,000 people worldwide.

As part of the integration, Dr John Stageman, vice-president of AZ's biopharmaceutical strategic planning, will act as interim head of the UK Cambridge site.

AZ purchased CAT in June 2006 in order to boost by 25 per cent the number of biologics in its product pipeline by 2010. The company acquired MedImmune in 2007.

David M Mott, MedImmune's CEO, said: "The new MedImmune is now the operationally independent and strategically aligned biologics business unit of AZ. Bringing together the biologics expertise of CAT, MedImmune and AZ allows us to preserve MedImmune's traditional biotech agility and entrepreneurial spirit while encouraging strategic collaboration and cross fertilization of ideas under AZ's world-class research umbrella."

Dr Stageman added: "AZ's biologics capabilities have been enhanced significantly by the acquisitions of CAT and MedImmune to create a more robust, highly competitive and fully integrated biotechnology business. The scientific, technical and medical expertise that this team brings together is world class in discovering, developing, manufacturing and commercialising biopharmaceutical products."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Anthill_icon_Green_17_Multi-channel.png
Can you access your own content?
The rapid development of multichannel communication opens new opportunities to provide high-value experiences for healthcare professionals and gives you more places than ever to tell your product story. But unless...
How will capitated budgets affect NHS spending?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the implications of a single budget covering all the physical, mental and social care needs of patients in an STP...
Dissecting adherence to personalise patient support
Across the healthcare and pharmaceutical industries, the initiatives to better understand the patient journey and lower healthcare costs have been growing in magnitude. One solution that has repeatedly been raised...

Infographics